The groundbreaking success of Sildenafil undeniably reshaped the medication landscape, but placing funds in companies strongly reliant on off-patent versions presents a complex picture. While early returns were impressive, the end of patents and the appearance of cheaper alternatives have eroded market share. Consequently, a thorough evaluation of